MTOR and breast cancer: Based on these results showing an apparent relationship between AKT/mTOR signaling and ATRAP expression in breast cancer cells, we next used the mTOR inhibitor rapamycin (20 nM) to examine whether AKT/mTOR signaling was required for ATRAP-mediated breast cancer progression.